RPG Life Sciences Approves ₹243 Crore API Subsidiary Investment And Acquisition

29 July 2026

RPG Life Sciences Ltd.

Bulk drug intermediates supplier for complex API ingredients

Recent Events

RPG Life Sciences Partners With InvAscent In ₹243.33 Crore API Investment

RPG Life Sciences Agrees To Acquire Raghava API Business For ₹135 Crore

RPG Life Sciences Approves Up To ₹135 Crore Raghava API Acquisition

RPG Life Sciences Approves ₹135 Crore API Business Acquisition

RPG Life Sciences Carves Out API Business, Raises ₹243 Crore From InvAscent

Get features of